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Background: The effectiveness of specific regimens of adjuvant therapy for gastric cancer has not been verified by
large clinical trials. Recently, several large trials attempted to verify the effectiveness of adjuvant therapy. The
Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer in Japan, a randomized controlled trial of adjuvant S-1
therapy for resected gastric cancer, demonstrated significant improvement in overall and relapse-free survival,
compared to surgery alone. To evaluate value for money of S-1 therapy, cost-effective analysis was carried out.
Methods: The analysis was carried out from a payer’s perspective. As an economic measure, cost per
quality-adjusted life-year (QALY) gained was estimated. Overall survival was estimated by the Kaplan-Meier
method, up to 5-year observation. Beyond this period, it was simulated by the modified Boag model. Utility score
is derived from interviews with sampled patients using a time trade-off method. Costs were estimated from trial
data during observation, while in the period beyond observation they were estimated using simulation results.
To explore uncertainty of the results, qualitative and stochastic sensitivity analyses were done.
Results: Adjuvant S-1 therapy gained 1.24 QALYs per patient and increased costs by $3,722 per patient for over
lifetime (3% discount rate for both effect and costs). The incremental cost-effectiveness ratio (95% confidence
intervals) for over lifetime was estimated to be $3,016 ($1,441, $8,840) per QALY. The sensitivity analyses showed
the robustness of these results.
Conclusion: Adjuvant S-1 therapy for curatively resected gastric cancer is likely cost-effective. This therapy can be
accepted for wide use in Japan.
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Gastric cancer is a major health problem worldwide. It
ranks second in all causes of death from cancer, with
about 700,000 confirmed deaths annually [1,2]. In Japan,
although its mortality ranks also second and has de-
creased in recent years, it still has the highest incidence
despite advances in prevention and treatment [3]. While
the internationally accepted standard treatment for pa-
tients with potentially resectable disease was surgery alone
[4,5], meta-analyses of adjuvant chemotherapy for gastric
cancer during the last few decades have shown reductions
in mortality up to 18% [6,7]. However, these reductions
were considered insufficient to change clinical practice.* Correspondence: akih@k3.dion.ne.jp
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reproduction in any medium, provided the orRecently, the effectiveness of specific regimens for re-
sectable gastric and/or gastroesophageal cancer has been
verified in large clinical trials. The chemoradiation ther-
apy (INT-0116) in the US in 2001 [8], the perioperative
chemotherapy (MAGIC) in Europe in 2006 [9], and the
postoperative chemotherapy (ACTS-GC) in Japan in
2007 [10,11] improved significantly overall survival (OS),
and relapse-free survival (RFS) or progression-free sur-
vival (PFS), compared to surgery alone.
These studies have led to a new phase in the treatment of
gastric cancer, even though there are several issues
under discussion concerning them [5,12,13]. Postoperative
chemoradiotherapy, perioperative triplet-chemotherapy,
and postoperative S-1 mono-chemotherapy are now the
standard therapies in the US, Europe and Japan, respect-
ively [5,12]. Also, the status of adjuvant treatment of gastricral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Characteristics of subjects and clinical outcomes
S-1 therapy Surgery alone
Number of patients 529 530
Age (median) 63 63
Sex (male) 367 369















Adverse events more than grade 3* 155 80
Total no. of relapses 162 221
% %
5-year survival (95% CI) 72 (68–76) 61 (57–65)
5-year relapse-free survival (95% CI) 65 (61–70) 53 (49–57)
The results are presented according to ITT (intention to treat): * The results
from the safety analysis.
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current standard of care across national boundaries.
Under these circumstances, from a perspective of
healthcare policy, in choosing the best treatment among
the different options available, clinical benefits of treat-
ments should be balanced against the effects on costs,
since rapid growth in healthcare expenditures creates an
unsustainable burden. However, economic evaluation of
adjuvant therapy for gastric cancer has been greatly
lacking.
Our objective was to estimate the cost-effectiveness of
adjuvant S-1 therapy in Japan. This study would provide
basic information on the cost-effectiveness of adjuvant
therapy for gastric cancer in Japan.
Methods
Analytical overview
Economic analysis was conducted retrospectively based on
the ACTS-GC (ClinicalTrials.gov number, NCT00152217)
[10,11]. Patients with completely resected stage II/III gastric
cancer, who underwent gastrectomy with extended (D2)
lymph-node dissection, were randomly assigned to either
oral S-1 (40 mg/m2 per day) for 1 year after surgery
(n = 529) or surgery alone (n = 530). S-1 is an orally active
combination of tegafur, gimeracil, and ostracil in a molar
ratio of 1:0.4:1.
As a type of economic analysis [14], a cost-effective
analysis was performed. Incremental costs and effectiveness
of adjuvant S-1 therapy compared to surgery alone were
evaluated. According to the effectiveness measure used
(i.e., life-years (LYs) gained and quality-adjusted life-years
(QALYs) gained), incremental cost-effectiveness ratios
(ICERs) were calculated. In addition, confidence intervals
of ICER were also estimated using the non-parametric
bootstrap method [14].
The payer of National Health Insurance in Japan was
adopted as a perspective of economic analysis [14].
Therefore, for costs, direct medical care costs (e.g., costs
of tests, drugs, health care personnel, etc.) were exam-
ined, whereas indirect costs (e.g., time costs or produc-
tion loss among patients and their families) were not
considered. As a time horizon for evaluation, three levels
of time periods (i.e., observational period [5 years], 10-
year follow-up and over lifetime) were considered. As
the base case analysis, over lifetime was used, since this
period covered long-term consequences of treatment on
health and costs.
Effectiveness
The results of the ACTS-GC were used as evidence of
effectiveness in the economic analysis. The clinical re-
sults have been presented in detail elsewhere [10,11]. As
is shown in Table 1, between the S-1 therapy group and
the surgery alone group, no statistical differences wereobserved in age, sex, pathological tumor stage, or type of
lymph-node dissection and gastrectomy. The incidence
of adverse events more than grade 3 in the S-1 therapy
group was significantly higher than that in the surgery
alone group. The OS and RFS rates in the S-1 therapy
group were significantly higher than those in the surgery
alone group [10,11].
Using patients’ data, OS and RFS were estimated
by the Kaplan-Meier method, up to 5 years from
randomization. Beyond the observation period of 5 years,
OS was simulated using the Boag model [15] combined
with the independent competing risk model [16,17]
(Figure 1). While there is no explicit standard for ex-
trapolation beyond the observation [18], this model
showed an extreme goodness of fit, validated by observa-
tional data [17].
In this model, OS curve was decomposed into two
components: the disease-specific survival curve and the
disease-independent survival curve. In the first curve,
only disease-specific (i.e., gastric cancer) deaths were
counted as events, and all other deaths were censored;
the converse applies to the second curve. The disease-
Figure 1 Survival curve and extrapolated survival estimate. (A) Survival curve in the S-1 and the control groups, (B) Survival curves using
Boag and competing risk models and relapse-free survival curve in the S-1 group.
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metric model. As death from disease becomes rarer with
increasing time, the disease-related survival curve ap-
proximates to a plateau (Figure 1B, gastric cancer related
survival curve using the Boag model).
Instead of the original log-normal model, the log-
logistic model was adopted in this analysis, according to
the analysis of observational data of this trial. This log-
logistic model was also supported by the analysis of
a large database for gastric cancer in Japan [19]. In
selecting a model among log-logistic, log-normal and
Weibull models, Akaike’s Information Criteria (AIC)
were used [20].
The second curve, disease-independent curve was sim-
ulated by the survival curve of the general population
matched for age and sex of the subjects, using national
life tables (Figure 1B, general population survival curve).
The two simulated curves were then extended over life-
time and were recombined (multiplied) into a complete
overall survival curve, using the competing risk model(Figure 1B, simulated survival curve using competing risk
model). Under the competing risk model, the simulated
survival rate is simply derived from multiplying the
disease-related survival rate by the disease-independent
survival rate. The life years were estimated as the
area under the curve (AUC). The survival rate and
variance were obtained by maximum likelihood estima-
tion of the Boag parameters (i.e., the cure rate, the
mean and standard deviation of log survival time). A
detailed description of QALY calculation is presented
in Appendix.
For RFS, the log-logistic model was also adopted,
according to the analysis of observational data in the
study [10,11] and AIC (Figure 1B, relapse-free survival
curve).
The mean number of LYs and relapse-free LYs for pa-
tients in each group was estimated as the area under the
OS and RFS curves, respectively [21]. In addition,
QALYs were calculated from OS and RFS by weighting
each survival in each interval by a utility value for each
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gery and relapse). Utility values for these health states
were derived from an interview with random samples of
patients in remission after surgery (n = 23) and consecu-
tive patients with relapse (n = 21), with informed con-
sent, by using a time trade-off method. No statistical
difference was observed in key characteristics between
these samples and the population subjects [10,11]. The
mean (and S.D.) of the utility values for remission after
surgery and for metastasis were 0.851 (0.121), and 0.349
(0.208), respectively. When the risk of relapse has dimin-
ished, the change in utility value for remission after
surgery would be considered to be the same as that of
the general population. We applied the weighting by age
for each year of follow-up, based on a population survey
for quality of life in Japan [22].
The utility reduction associated with adverse events was
adjusted through the method adopted by Aballea, et al
[23]. The utilities for hospitalization and the adverse
events with grade 4 were reduced by 50%. Also, 23%, 19%
and 36% reduction were applied for nausea, vomiting and
stomatitis, and diarrhea, respectively.
Cost
Costs incurred for resources used during trial and subse-
quent follow-up were estimated from trial data and
their extrapolation. Resource utilization during trial and
follow-up was derived from individual patient history
data. Since observations on many patients are censored
in a clinical trial, subsequent costs are unknown. To
correct for censoring, the inverse probability weighting
method [21] was applied during the observation period.
Beyond the observation period, costs related to gastric
cancer (i.e., those for recurrence and end-of-life) were
estimated using the simulation results. Costs were
estimated from the National Health Insurance perspec-
tive using the National Health Insurance reimbursement
list and drug price for 2007 [24,25]. The costs of adverse
events and a recurrence were estimated based on
patients’ records during observation. The chemotherapy
for the majority of recurrence was implemented
according to the first-line therapy in the Japanese guide-
lines [26].
As most health economic guidelines (e.g., the UK,
Canada, Netherlands, Germany and the US) indicated,
unrelated health care costs in the later years of life were
not included in this analysis [14]. All costs were
converted from Japanese yen to US dollars based on
OECD purchasing power parity in 2007 ($1 = \120) [27].
Discount
Discounting for the time value of money was applied to
both costs and effectiveness. In the base case analysis,
both costs and effectiveness accruing beyond 1 year werediscounted to present values at a rate of 3%, following
the recommendations of the US Panel on Cost-
Effectiveness in Health and Medicine [28]. However, cur-
rently, much debate still surrounds two major points:
the underlying discounting model and the differential
discount rate for health and cost [28-30]. Therefore, the
impact of discounting on the results was examined
extensively by sensitivity analysis.
Sensitivity analysis
The uncertainty of the results was explored by stochastic
and qualitative sensitivity analyses of important factors
[14,31,32]. The impact of uncertainty on the estimated
ICER due to the stochastic nature of sampled data was
analyzed by applying a non-parametric bootstrap re-
sampling technique (i.e., 5000 times) to both costs and
effectiveness. Also, cost-effectiveness acceptability curve
(CEAC) and net monetary benefit (NMB) analyses
[31,32] were performed. A number of qualitative one-
way and two-way sensitivity analyses were conducted to
explore the impact of alternative parametric assumptions
on the results. These included alternative assumptions
concerning time horizon, key cost parameter, recurrence
rate, utility value, discount rate and simulation method.
Also, the exclusion of end-of-life costs due to gastric
cancer was examined by a sensitivity analysis, under the




The mean QALYs (3% discount rate) in each group are
shown in Table 2. For 5-year observation, 10-year
follow-up and over lifetime, the mean QALYs per patient
for adjuvant S-1 therapy were 3.11, 5.08 and 8.65, re-
spectively. Those for surgery alone were 2.84, 4.45 and
7.41, respectively. Adjuvant S-1 therapy gained 0.27, 0.64
and 1.24 QALYs per patient, for each period, respectively
(p < 0.05). The difference in QALYs was relatively
smaller than that in LYs for 10-year follow-up and over
lifetime.
Cost
The mean costs (no discounting) per patient in each
group for the 5-year observation are shown in Table 3.
The mean total cost per patient was $11,103 in the S-1
therapy group, and $7,761 in the surgery alone group.
The costs of recurrence and end-of-life were the major
component in both groups. Although S-1 therapy added
over $4,000 per patient to the ingredient cost of surgery
alone, this was partly offset by the reduction of costs in
recurrence and end-of-life of gastric cancer. As is shown
in Table 2, for 5-year observation, 10-year follow-up and
over lifetime, adjuvant S-1 therapy increased costs (3%
Table 2 Incremental effectiveness and costs of adjuvant S-1












3.11 2.84 0.27 (0.11 – 0.42)
10-year
follow-up
5.08 4.45 0.64 (0.28 – 0.99)




10,802 7,408 3,389 (2,616 – 4,174)
10-year
follow-up
12,110 8,523 3,585 (2,750 – 4,411)
Over lifetime 13,057 9,346 3,722 (2,911 – 4,512)
Incremental cost-effectiveness ratio





12,716 (6,428 – 34,018)
10-year
follow-up
5,608 (2,855 – 14,569)
Over lifetime 3,016 (1,441 – 8,840)
CI = confidence interval; QALYs = quality-adjusted life-years.
Table 3 Mean costs per patient during observation
period (no discounting)
Item S-1 therapy Surgery alone
Unit cost ($) Quantity Cost ($) Quantity Cost ($)
(No. of units) (No. of units)
Consultation
Outpatient: 5.8 22.4 131 8.3 49
Treatment
S-1 drug (mg): 0.3 15,156 4,367 NA
Prescription: 4.9 10.5 52 NA
Tests
Imaging tests
CT: 124.3 5.1 629 4.9 608
Chest X-ray: 21.1 2.0 42 2.0 43
Echogram: 44.2 1.8 80 1.9 85
Endoscopy: 95.0 1.5 147 1.7 164
Others: 156.0 0.2 34 0.2 38
Laboratory tests
Blood test: 35.0 21.3 746 9.1 319
Tumor markers: 33.3 8.6 286 8.6 288
Adverse effects
Anti-ulcerants: 6.0 0.3 2 0.2 1
Anti-biotics: 15.4 0.2 3 0.1 1
Anti-diarrhoeals: 5.4 0.2 1 0.1 0
Anti-emetics: 64.8 0.1 9 0.0 3
G-CSF: 106.9 0.0 3 0.0 0
Blood transfusion: 188.5 0.0 0 0.0 1
Recurrence
S-1: 3,694 0.1 487 0.3 1,394
Paclitaxel: 5,298 0.1 422 0.0 101
S-1 + cisplatin: 5,594 0.0 227 0.1 244
S-1 + paclitaxel: 5,247 0.0 162 0.0 129
5FU +methotrexate: 4,748 0.0 65 0.0 144
Irinotecan + cisplatin: 5,197 0.0 162 0.0 43
Others: 4,892 0.0 211 0.0 201
End of life
Drugs/injections 0.3 1,064 0.4 1,367
Treatments 0.3 233 0.4 321
Operations/anesthesia 0.3 213 0.4 296
Diagnostic tests 0.3 221 0.4 353
Total costs per patient 11,103 7,761
(SD) (6,832) (6,787)
NA = not applicable.
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respectively, compared to surgery alone (p < 0.05).
Incremental cost-effectiveness ratio
As is shown in Table 2, as the base case, the ICER (95%
confidence intervals) for over lifetime was estimated to
be $3,016 ($1,441, $8,840) per QALY, using the boot-
strap method (3% discount rate for both effect and cost).
Those for 5-year observation and 10-year follow-up were
$12,716 and $5,608 per QALY, respectively. There is
little difference between costs per LY gained and costs
per QALYgained.
Sensitivity analysis
The results of probabilistic sensitivity analyses are shown
in Figures 2. Figure 2A shows ICER (cost per QALY
gained) scatter plots based on 5,000 samples. All points
resided in the northeast quadrant (i.e., more effective
and more costly). All points were located under the di-
agonal line indicating the ICER of $50,000 per QALY
gained. The CEAC is presented in Figure 2B. If the value
of an additional QALY was $6,220, the likelihood of S-1
therapy being cost-effective was 95%. The NMB curve is
shown in Figure 2C. The value of an additional QALY
was $3,016, when the NMB curve crossed the horizontal
axis.A number of qualitative sensitivity analyses are shown
in Tables 2 and 4. As to time horizon (Table 2), from 5-
year observation to over lifetime, ICER varied from
$12,716 to $3,016, as mentioned before.
Figure 2 Stochastic sensitivity analyses. (A) Incremental cost-effectiveness scatter plot of adjuvant S-1 therapy, (B) Cost-effectiveness
acceptability curve of adjuvant S-1 therapy, (C) Net monetary benefit curve of adjuvant S-1 therapy with 95% confidence intervals.
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costs and effect showed a relatively small change in ICER.
ICER was lowest ($2,194/QALY) without discounting and
highest ($3,628/QALY) at the discount rate of 5% for both
costs and effectiveness. ICER increased with increase in
discount rate of both cost and effect.The results of one-way sensitivity analyses are shown
in Table 4. Variations in recurrence rate, utility value,
QALYs, the acquisition cost of S-1, recurrence cost, end-
of-life cost, and simulation model did not greatly change
ICER. With variations of these variables, ICERs varied
from $1,901 to $7,696 per QALY gained.
Table 4 One-way sensitivity analysis of important factors
Factor Cost-effectiveness ratio
($/QALY gained)









(95% CI: 0.788 - 0.898)
2,825 ‐ 3,231
Metastasis (95% CI: 0.231 - 0.473) 2,998 ‐ 3,032
QALY gained (95% CI: 0.48 – 1.96) 1,901 ‐ 7,696
Recurrence cost
(95% CI: $2,032 - $2,422)
2,834 ‐ 3,149
End of life cost
(95% CI: $3,997 - $4,766)
2,682 ‐ 3,302
Exclusion of end-of-life costs due to
gastric cancer
3,677
S-1 cost (95% CI: $4,322 - $4,772) 2,810 ‐ 3,173
Total cost difference
(95% CI: $2,911 - $4,512 )
2,347 ‐ 3,638
Discount rate: 3% for both cost and effectiveness, Period: lifetime.
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From the perspective of the National Health Insurance
in Japan, this cost-effectiveness analysis showed that S-1
adjuvant therapy for gastric cancer gained LYs and
QALYs, while it increased costs, compared with surgery
alone (Table 2). The ICER of S-1 therapy can be ranked
close to the top of the league table of cost-utility in
oncology [33]. There is some consensus about the
threshold of willingness to pay for additional QALY
internationally (e.g., $50,000 in the US, £30,000 in the
UK, or AUS $42,000 in Australia) [34]. A recent review
suggested that the plausible threshold is $109,000/QALY,
rather than $50,000/QALY [35]. In Japan, the social
value (i.e., willingness to pay) for QALY gained was esti-
mated to be from $53,000 to $56,000 by a nationwide
mail survey using conjoint analysis [36]. Since the ICER
of S-1 therapy is far below these thresholds, it is consid-
ered acceptable.
There has been little evidence on economic evaluation of
adjuvant therapy for gastric cancer. A cost-effectiveness
analysis evaluating postoperative chemoradiotherapy for
gastric cancer in the US showed that the incremental cost-
effectiveness ratio was $38,400 per QALY gained [37]. This
ratio is 14 times higher and less efficient than that in our
study, although several factors such as clinical practice pat-
terns and relative costs should be considered in transferring
evaluation data [14]. Moreover, since there is no genuineutility information in calculating QALY in the report [37],
its validity and plausibility would be questionable.
The results of this study are subject to uncertainty and
assumptions. To estimate stochastic uncertainty of ICER
due to sampling variation or error, probabilistic sensitiv-
ity analyses [14,31,32] were performed (Table 2, Figure 2).
Cost-effectiveness scatter plots showed that all points of
ICERs were located under the diagonal line indicating
$50,000/QALY. CEAC and NMB curves give more
information. If a decision-maker was willing to pay
$6,220 to achieve an additional QALY, the likelihood of
S-1 therapy being acceptable as cost-effective was 95%
(Figure 2B). The NMB curve shows that S-1 therapy was
beneficial, if a decision-maker was willing to pay $2,782
(Figure 2C). These values are extremely low compared
with the thresholds (e.g., $50,000).
The time horizon is an important issue to sufficiently
capture relevant costs and health outcomes of S-1 adju-
vant therapy. The observation period of the ACTS-GC,
5 years was limited. While most costs were incurred
mainly in the observational period, LYs gained would
continue after it. In this study, a simulation model was
used to extrapolate its results. There is a variety of ways
for simulation [18], but no uniform methodology avail-
able. We used the Boag model, which is indicated to be
predictive for prognosis of gastric cancer [17]. In a sensi-
tivity analysis, the ICER of the observational period was
much higher than that of over lifetime (the base case),
but it is very low compared with the thresholds. Also,
the results of other simulation methods indicated similar
results. The exclusion of end-of-life costs due to gastric
cancer slightly increased the ICER, but it still remained
far under the threshold (Table 4). These analyses show
the robustness of this study.
The key drivers of cost-effectiveness results of S-1 are
mainly the acquisition cost of S-1 and the costs related
to recurrence and death. The S-1 therapy partly offset
the acquisition cost of S-1 by the savings achieved by re-
duction of these costs. In one-way sensitivity analysis
(Table 4), varying recurrence rates and costs of recur-
rence and end-of-lie did not have substantial impact on
cost-effectiveness. Varying acquisition cost, which was
the other cost driver, also did not have major impact on
cost-effectiveness (Table 4). The sensitivity analysis of
total cost corresponded with these results.
Cost-effectiveness analysis using QALYs offers the op-
portunity to consider both quantity and quality of sur-
vival. However, no substantial difference in ICERs was
observed between cost per LY gained and QALY gained
(Table 2). In this study, utility values were derived from
a relatively small number of patients with gastric cancer,
but this is the first study which directly evaluated the
utilities among patients with gastric cancer. These values
are similar to those observed for general cancer (i.e,
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Canadian survey among the general population [38].
The sensitivity analysis on range of utility values for re-
mission after surgery and metastasis revealed no major
change in cost-effectiveness (Table 4). In a sizable frac-
tion of cost-effectiveness analyses, utility weighting was
indicated not to substantially alter the estimated cost-
effectiveness of an intervention [39]. It is thus suggested
that sensitivity analyses using ad hoc adjustment or weight
from the literature may be sufficient. Our results support
this conclusion.
The impact of discounting for the time value of money
on the results was examined extensively by two-way sen-
sitivity analysis. Although ICERs were more sensitive to
effectiveness discounting than cost discounting, there
was no substantial change in cost-effectiveness. The
main reason is likely to be that major costs were in-
curred during the early phase of follow-up and improved
survival continued for a relatively long time.
There are additional limitations in the analysis that
should be commented on. First, the perspective of this
analysis is that of a payer for healthcare, rather than a
society. From a societal perspective, the range of costs is
broader and includes other costs such as indirect costs.
Since S-1 therapy increased OS and decreased recur-
rence, these factors would reduce indirect costs and de-
crease its ICER.
Second, the issue of generalizability of this study to
other countries should be carefully examined. S-1 is
widely used in Asian countries (e.g., Japan, Korea,
Singapore and China). However, it is difficult to deter-
mine the relative effectiveness of S-1, compared with the
preoperative chemoradiotherapy in the US and the pre-
operative triplet-chemotherapy in Europe, since there is
no direct comparison among them [8-10]. Moreover,
there are several critical arguments around these studies.
For example, the INT-0116 study attracted some criti-
cism on the grounds of poor standardization of surgery
and insufficient extended dissection of regional lymph
nodes [5]. Thus it was argued that the chemoradiation
component of the adjuvant treatment had compensated
for less-than-ideal surgery. On the other hand, the qual-
ity of the MAGIC trial was pointed out to be much
poorer than that of the INT-0116 study, in the areas of
active quality control of surgery, data management, and
compliance with protocol [12]. As to S-1, a difference in
S-1 phamacokinetics was observed between Asians and
Caucasians [13].
Recently, although the subjects did no have resect-
able gastric cancer like in this study, but advanced gas-
tric cancer, the First-Line Advance Gastric Cancer
Study (FLAGS) [40], a multinational trial, showed that
cisplatin/S-1 was statistically non-inferior in overall
mortality to cisplatin/5-FU and showed a significantlyimproved safety profile in Western countries. While
S-1 is now approved by the EMEA in European coun-
tries, an international head-to-head comparison be-
tween S-1 therapy and the Western standard therapies
will be required to confirm relative effectiveness and
cost-effectiveness of S-1 therapy.
Conclusion
S-1 adjuvant therapy for gastric cancer gained LYs and
QALYs, while it increased costs, compared with surgery
alone. The ICER of S-1 therapy can be ranked close to
the top of the league table of cost-utility in oncology and
far below the social value or threshold for QALY gained
in Japan. S-1 therapy for curatively resected gastric can-
cer is likely cost-effective. This therapy can be accepted
for wide use in Japan.
Appendix: the method of QALY calculation
A.1 Calculation of QALY
QALYi (u), defined as the QALY at year i, was calcu-
lated by the following Equation (1), in which uNR repre-
sents the utility value of no relapse and uR represents
the utility value of relapse.
QALYi uð Þ ¼ uNRmean relapse−free rateþuR
 mean survival rate–mean relapse−free rateð Þ
ð1Þ
If d is the discount rate, the equation becomes QALY
(u)=Σid(i-1) × QALYi(u).
The mean rate of survival was calculated as the area
under the curve (AUC) of OS, and the mean rate of
relapse-free survival was calculated as the AUC of RFS,
using the trapezoidal approximation rule.
A.2 Estimate of survival curves of lifetime OS
When estimating the survival curves of lifetime OS, it
was assumed that some patients in this study would be
cured in response to treatment. This model is called the
Boag (cure) model or mixture cure model. This statis-
tical model assumes a mixed distribution of survival
time among cured patients and uncured patients.
Y is defined as a variable indicating the presence or
absence of cure in patients. Y = 0 stands for cure, and
Y = 1 stands for non-cure. If p is defined as the probabil-
ity of non-cure as represented by p = Pr(Y = 1), and T is
a random variable indicating the survival time, the cu-
mulative distribution function of T is represented by the
following Equation (2).
F tð Þ ¼ Pr T≤tð Þ
¼ p⋅Pr T≤t=Y ¼ 1ð Þ þ 1−pð Þ⋅Pr T≤ t=Y ¼ 0ð Þ
ð2Þ
It was assumed that no events occur because of cure in
cured patients. In other words, if Pr(T ≤ t|Y=0) = 0, the
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This is referred to as a cure model.
F tð Þ ¼ p⋅ t=Y ¼ 1ð Þ ð3Þ
In the cure model, the probability density function f(t)
and survival function S(t) are represented by the following
Equations (4).
f tð Þ ¼ p⋅f t=Y ¼ 1ð Þ
S tð Þ ¼ 1−pð Þ þ p:S t=Y ¼ 1ð Þ ð4Þ
A logistic regression model was assumed to calculate
the probability of non-cure p. In this model, p is calcu-
lated by Equation (5), in which z is a covariance vector,
x = (1,z)' (' stands for vector transposition), and b is a
regression coefficient vector of covariance.
p xð Þ ¼ exp b
0xð Þ
1þ exp b0xð Þ ð5Þ
The Boag model [15] assumes a log-normal distribu-
tion for the survival time of uncured patients, but a log-
logistic distribution was assumed in the present study.
Furthermore, sensitivity analysis was also performed as-
suming a log-normal distribution and a Weibull distri-
bution, and the maximum likelihood method was used
to estimate the parameters using observational data of
the ACTS-GC trial [10,11]. The goodness of fit of the
model was evaluated with Akaike’s information criteria
(AIC). A log-logistic distribution has two parameters θ =
(γ, λ)′, and the survivor function is as follows:
S t; θð Þ ¼ 1
1þ λ⋅tγ ð6Þ
The statistical software package SAS (version 9.2)
was used to fit the data to the aforementioned
models, and the probabilities of non-cure (p) were
estimated to be 0.306 and 0.422 in the S-1 group
and surgery alone group, respectively. The log-
logistic distribution parameters λ and γ were 0.9724
and 0.4121, respectively. The value of AIC for the
log-logistic model was 1,678. Those for log-normal
and Weibull models were 2,113 and 2,117, respect-
ively. The programs used to estimate the model pa-
rameters were the SAS macro for survival models
with a cured fraction (Mixture Cure Models).
To examine the validity of the log-logistic model, the
distribution of survival time of cured patients was also
analyzed using data on patients with gastric cancer
obtained from the Cancer Institute Hospital (1946–
2004), which has an open database [19]. The approach
used was as follows: First, data on patients who met
the following 6 eligibility criteria corresponding to the
ACTS-GC trial (n = 1,457) were extracted from all data
(n = 13,740). The median age of the patients extractedfrom the database was 57 years, which was 6 years
younger than the median age of 63 years in the ACTS-
GC trial. Kaplan-Meier curves were plotted using the
extracted patient data, defining only death from gastric
cancer as an event. The curve reached a plateau after
about 20 years (corresponding to an age of 77 years).
These data were used for cure models assuming a
Weibull distribution, log-normal distribution, and log-
logistic distribution. The goodness of fit of the data as
indicated by the AIC was best for the log-logistic dis-
tribution. While the value of AIC for the log-logistic
model was 1,845, those for the log-normal and Weibull
models were 2,071 and 2,105, respectively.
Eligibility criteria of the ACTS-GC trial
1) A histologically confirmed diagnosis of gastric
cancer
2) Lymph-node dissection of D2 or greater, with a
curability of A or B
3) Stage II, IIIA, or IIIB disease
4) No liver metastasis, hematogenous metastasis, or
distant metastasis
5) An age of 20 to 80 years
6) No previous treatment (chemotherapy,
radiotherapy) received
Finally, the OS curve was constructed by combin-
ing the disease-specific survival curve (cure paramet-
ric model) and the disease-independent survival
curve (the general population matched for age and
sex of the subjects) based on the competing risk
model. The actual calculation was done using a
competitive risk model and the following Equation
(7), in which SB(t) stands for the survival rate in the
disease-specific survival curve (= cure model curve),
SC(t) stands for the survival rate of the general
population in the disease-independent survival curve,
and SA(t) is the estimated rate of OS after the obser-
vation period. The structure of the OS curve was
presented in Figure 1B.
SA tð Þ ¼ SB tð Þ SC tð Þ ð7Þ
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